Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Prostate-specific antigen (PSA) is widely used for prostate cancer screening.
• The clinical utility of PSA screening in asymptomatic men remains controversial.
• Concerns include PSA's limitations in early cancer detection and the potential for overdiagnosis and overtreatment of indolent disease.

Purpose of the Study:

• To evaluate the controversial value of PSA screening for prostate cancer in asymptomatic men.
• To discuss the balance between the benefits of reduced mortality and the harms of overdetection/overtreatment.
• To highlight the importance of informed consent regarding PSA screening risks and benefits.

Main Methods:

• Review of randomized prospective trials on PSA screening.
• Analysis of the limitations of PSA as a diagnostic marker.
• Discussion of treatment uncertainties for localized prostate cancer.

Main Results:

• PSA screening may offer a modest reduction in prostate cancer mortality.
• The overall benefit of PSA screening is debated due to potential overdetection and overtreatment.
• Clarity on the optimal treatment for localized prostate cancer is lacking.

Conclusions:

• The decision to screen for prostate cancer using PSA requires careful consideration of risks and benefits.
• Informed consent is crucial, ensuring men understand the potential harms and benefits of early detection.
• Emerging biomarkers like PSA isoforms and PCA3 may offer improved early detection capabilities.